OTCMKTS:MEDXF Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis → Heard about the 72-Hour Profit Surge? Read this… (From DTI) (Ad) Free MEDXF Stock Alerts $1.14 -0.04 (-3.38%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.1850-Day Range$1.10▼$1.4552-Week Range$0.90▼$2.56Volume39,600 shsAverage Volume19,097 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Medexus Pharmaceuticals alerts: Email Address Ad DTIDo NOT Buy the Fidelity and Blackrock Bitcoin ETFs - Here’s whyBefore you buy the newly approved Bitcoin ETFs… Take a look at this “Better than Bitcoin ticker” you can buy in any regular brokerage account. Why? Because it’s been shown to outperform Bitcoin by 10X or more during the past four bull runs… For example, while Bitcoin surged 985% during the last bull run in 2021… This is your best chance at it. About Medexus Pharmaceuticals Stock (OTCMKTS:MEDXF)Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.Read More MEDXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDXF Stock News HeadlinesMay 3, 2024 | seekingalpha.comCPHRF Cipher Pharmaceuticals Inc.April 3, 2024 | seekingalpha.comMDP:CA Medexus Pharmaceuticals Inc.February 12, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Slashed Next Year's EstimatesFebruary 9, 2024 | wsj.comMedexus Pharmaceuticals Inc.February 9, 2024 | realmoney.thestreet.comMedexus Pharmaceuticals just downgraded at Raymond James, here's whyFebruary 7, 2024 | finance.yahoo.comMedexus Announces Fiscal Q3 2024 ResultsJanuary 8, 2024 | finance.yahoo.comHealth Canada Accepts for Review Medexus's New Drug Submission for Topical TerbinafineNovember 18, 2023 | seekingalpha.comMEDXF Medexus Pharmaceuticals Inc.November 8, 2023 | msn.comMedexus Pharmaceuticals reports Q2 resultsOctober 16, 2023 | finance.yahoo.comMedexus Fully Repays Convertible Debentures In Cash At MaturitySeptember 28, 2023 | finance.yahoo.comMedexus and medac Agree to Amend US Treosulfan AgreementSeptember 21, 2023 | finance.yahoo.comMedexus Holds Annual Meeting of Shareholders and Announces Election of DirectorsSeptember 5, 2023 | finance.yahoo.comMedexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of UnitsSeptember 5, 2023 | markets.businessinsider.comMedexus Pharmaceuticals Inc (MDP) Receives a Buy from Stifel NicolausSeptember 5, 2023 | finance.yahoo.comMedexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion FacilityAugust 17, 2023 | finance.yahoo.comMedexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia BAugust 9, 2023 | finance.yahoo.comMedexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 MillionAugust 2, 2023 | msn.comMedexus Pharmaceuticals (MEDXF) Price Target Increased by 8.32% to 2.73August 2, 2023 | finance.yahoo.comMedexus Schedules First Fiscal Quarter 2024 Conference CallJuly 12, 2023 | finance.yahoo.comMedexus Announces Preliminary Revenue for Fiscal Q1 2024June 15, 2023 | finance.yahoo.comFDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric PatientsJune 14, 2023 | finance.yahoo.comMedexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference CallJune 1, 2023 | finance.yahoo.comMedexus to Participate in the LD Micro Invitational XIIIMay 10, 2023 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible DebenturesMay 10, 2023 | finance.yahoo.comMedexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible DebenturesSee More Headlines Receive MEDXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MEDXF CUSIPN/A CIKN/A Webwww.medexus.com Phone(514) 344-8765FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$17.50 Low Stock Price Target$17.50 Potential Upside/Downside+1,431.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Kenneth d'EntremontCEO & DirectorMr. Marcel Konrad (Age 48)Chief Financial Officer Comp: $585.05kMr. Ian C. Wildgoose BrownGeneral Counsel & Corporate SecretaryMs. Tina Byers CFAExecutive of Investor RelationsMr. Bill PoncySenior Vice President of Commercial Operations - United StatesMr. Brian PetersVice President of Sales & Marketing - United StatesMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors MEDXF Stock Analysis - Frequently Asked Questions Should I buy or sell Medexus Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MEDXF shares. View MEDXF analyst ratings or view top-rated stocks. What is Medexus Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued twelve-month price objectives for Medexus Pharmaceuticals' shares. Their MEDXF share price targets range from $17.50 to $17.50. On average, they expect the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 1,431.7% from the stock's current price. View analysts price targets for MEDXF or view top-rated stocks among Wall Street analysts. How have MEDXF shares performed in 2024? Medexus Pharmaceuticals' stock was trading at $1.89 at the start of the year. Since then, MEDXF shares have decreased by 39.6% and is now trading at $1.1425. View the best growth stocks for 2024 here. Are investors shorting Medexus Pharmaceuticals? Medexus Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 151,400 shares, an increase of 26.9% from the April 30th total of 119,300 shares. Based on an average daily trading volume, of 13,300 shares, the days-to-cover ratio is presently 11.4 days. View Medexus Pharmaceuticals' Short Interest. How do I buy shares of Medexus Pharmaceuticals? Shares of MEDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MEDXF) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.